Replimune Group Inc
replimune.comReplimune Group Inc (NASDAQ: REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. The company has not yet generated product revenue as of the fiscal year ended March 31, 2025, and funds operations primarily through equity issuances, including common stock and pre-funded warrants. Replimune is headquartered in the United States with significant research and development operations in the United Kingdom, exposing the company to British pound and euro exchange rate fluctuations. The company carries an accumulated deficit and reports net losses, reflecting its pre-commercial stage. CEO Sushil Patel signs filings as Chief Executive Officer and Director. The company has engaged its auditor since 2018 and files on the Nasdaq Global Select Market. Operations involve clinical trials and reliance on contract research organizations, contract manufacturing organizations, and third-party consultants. The company holds patents and plans to pursue patent term extensions upon any future FDA product approvals.
Products & Services
Replimune develops oncolytic immunotherapy product candidates for oncology indications. The filing references clinical trials and pipeline programs but does not name specific approved products as of the fiscal year ended March 31, 2025.
Revenue Model
Replimune has not reported product revenue as of the fiscal year ended March 31, 2025. The company funds operations through equity capital raises, including common stock offerings and pre-funded warrant issuances, net of issuance costs and underwriter fees.
Customers & Markets
End markets are oncology and cancer treatment. The company's potential customers upon commercialization would include healthcare providers and payors, including Medicare and commercial insurers, as referenced in the FY2025 10-K.
Geographic Exposure
Replimune is headquartered in the United States with significant research and development operations in the United Kingdom. The company sources consulting and other services in the United Kingdom and the European Union, creating exposure to the British pound and euro, as disclosed in the FY2025 10-K.
Financial Snapshot
Loading...
